From intuition to opportunity

When Jean-René Ricard chose Switzerland to create his pharmaceutical company Laboratoires OM in 1937, he showed the strength of his intuition and his acute sense for opportunities. Those two founding qualities have put down roots and flourished. Our management has the sense and the experience to listen to its intuition, and our sense of the right opportunity guides us constantly in our international development of our pharmaceutical products.

Focusing research energy

We have the advantage of the most precious research instrument. It is called "freedom". It allows us to limit ourselves to the domains that we know the best, such as immunology. Or, on the contrary, to spread our wings and establish ties with the cream of outside resources, such as pharmaceutical manufacturers, biotechnology companies and laboratories. And thanks to our small, flexible teams we are also free to pursue an exciting opportunity, for instance, in biotechnology research. Or simply turn the page.

Originality and harmony

Our research is inspired by an ideal: we want to create original pharmaceutical products capable of offering a genuine therapeutic "plus". Rather than overpower an illness, we prefer to treat the cause, restore normal conditions, compensate for imbalance and seek the best combination of effectiveness and tolerance. Do we sound too idealistic? Every day the success of our pharmaceutical products proves that our feet are on the ground.

In a key position

In the therapeutic niche markets where we choose to be active, for instance, chronic respiratory disease, rheumatoid arthritis, urinary tract infections, venous insufficiency or cystitis, our size and our know-how are major assets. We are positioned to play a long-term key role in the market for chronic affections, whose dynamic growth is driven by increasing life expectancy. Our positive vision is based on fact. The effectiveness of our products, such as Doxium, Dicynone, Broncho-Vaxom, Uro-Vaxom and Subreum, and the well-being that they promote win us the loyalty of clients.

Maximising international presence

Protecting our ideals whilst extending our presence to a maximum number of countries is, admittedly, not an easy ambition. It requires that we proceed with the strategist's patience and cool determination. Having selected a fresh terrain, we prepare the ground patiently, seeding new alliances and choosing our partners for their proven performance. And we reap the benefits: the ability to develop, alone or through third partners, whatever the nature of the market.

Concentrating manufacturing know-how

By grouping our manufacturing sites, we maintain our high production standards and concentrate the force of our know-how. Quality is our bottom line and we ensure it by the synergy between our human and technological resources and our close proximity to the markets and their needs. Indeed, apart from our own production, how else could we have become a trusted manufacturer for others in the pharmaceutical industry?

Safeguarding our autonomy

We prefer to be self-financing. Far from utopian, our independence is a deliberate strategy that gives us the freedom, when need be, to choose financial partners. In this way we are able to complete or enrich a specific pharmaceutical research project and ensure that it reaches the point where it will be profitable. While never relinquishing our patent rights or our freedom of action.

Initiative, the source of motivation

Sharing responsibility also means accepting others' mistakes. Fully aware of the pitfalls, we nevertheless encourage all forms of initiative, and have proved that saying "give it a try" instead of giving orders is the springboard to creativity. We also invest heavily in training, the finest source of motivation that was ever invented.

Aiming at excellence

Knowing our limits and making them a driving force, that is our formula for success. For more than sixty years, a David amongst the Goliaths, we have honed the values for which we are now looked up to: rigorous quality, flexibility, know-how and productivity. Is it any wonder that we are looking forward to the next sixty years?


Top of the page